Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Strategy
100%
Immune Thrombocytopenic Purpura
100%
Empiricism
100%
Corticosteroids
33%
Therapeutic Plasma Exchange
33%
Immunosuppression
22%
ADAMTS13
22%
Von Willebrand Factor Cleaving Protease
22%
Relapse-free Survival
22%
United States
11%
Clinical Trials
11%
Improved Outcomes
11%
Immune Response
11%
Rituximab
11%
Randomized Controlled Trial
11%
Precision Medicine
11%
Trial Design
11%
Proteasome Inhibition
11%
Standard of Care
11%
Immune Inhibition
11%
Autoimmune Disease
11%
Europe
11%
Remission
11%
Thrombocytopenia
11%
Surrogate Endpoint
11%
Nanobody
11%
Fever
11%
Caplacizumab
11%
Kidney Injury
11%
Platelet Count
11%
Preformed Antibodies
11%
Recurrence Rate
11%
Von Willebrand Factor
11%
Composite Endpoint
11%
Accruals
11%
Neurological Dysfunction
11%
Plasmin
11%
Microangiopathic Hemolytic Anemia
11%
Multiple Strategies
11%
Immune Destruction
11%
ADAMTS13 Protein
11%
Congenital TTP
11%
Low-dose Rituximab
11%
Recombinant ADAMTS13
11%
Pharmacology, Toxicology and Pharmaceutical Science
Thrombotic Thrombocytopenic Purpura
100%
Von Willebrand Factor Cleaving Proteinase
60%
Corticosteroid
30%
Rituximab
20%
Recurrence Free Survival
20%
Clinical Trial
10%
Randomized Controlled Trial
10%
Remission
10%
Recurrent Disease
10%
Thromboembolism
10%
Nanobody
10%
Kidney Injury
10%
Neurologic Disease
10%
Recurrence Risk
10%
Plasmin
10%
Caplacizumab
10%
Enzymes
10%
Proteasome
10%
Von Willebrand Factor
10%
Thrombocytopenia
10%
Autoimmune Disease
10%
Diseases
10%
Low Drug Dose
10%
Immunology and Microbiology
Thrombotic Thrombocytopenic Purpura
100%
Blood Plasma
30%
Immunosuppression
20%
Rituximab
20%
Recurrence Free Survival
20%
Immune Response
10%
Low Drug Dose
10%
Autoimmune Disease
10%
Caplacizumab
10%
Platelet Count
10%
Single-Domain Antibody
10%
Proteasome
10%
Plasmin
10%
Proteinase
10%
Protease
10%